Page 126 - CL Armchair Case
P. 126
Syprine, which, he tells me, had about $200,000 in sales
per month in the fall of 2012, but now has sales of $10
million a month, an increase that is due purely to price
increases by Valeant. Cuprimine is a similar story. In other
words, Valeant did exactly what Shkreli was hoping to do.
